Skip to contentB
BioCorRx Inc.
B
BICXBioCorRx Inc. Q3 2022 · 10-Q
Revenue$94.44K$94.44K+971.1% vs Q3 2021 Net Income-$951.01K-$951.01KN/M vs Q3 2021 EPS, diluted—
Operating Income-$1,029,128N/M Operating Cash Flowderived-$367,820N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCorRx Inc. · CIK 1443863 · Engraved from SEC EDGAR
Margins · derivedOperating margin-1089.7%+17450.0 pt vs Q3 2021
Net margin-1007.0%+14454.5 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end